Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Refereed conference paper presented and published in conference proceedings


引用次數
替代計量分析
.

其它資訊
摘要Background
Molecular profiling of tumour tissue to guide treatment of patients (pts) with advanced solid tumours has previously been reported. Most series were reported from large volume academic cancer centres in the West. There is a paucity of data reporting the experience and applicability of such an approach in Asia. We report our single-centre experience of conducting a prospective molecular profiling programme for pts in advanced solid tumours.

Methods
Pts with advanced solid tumours aged >/= 18 years, good performance status and archival tumour tissue available were prospectively consented. The RNA extracted from the FFPE tissue sections were subjected to RNA-sequencing using Archer FusionPlex Solid Tumor Kit and Archer Analysis Software 5.1. The putative gene translocations or alternative splicing were further confirmed with RT-PCR or FISH.

Results
253 pts consented between Feb 2017 and Feb 2019. Demographics: M:F 138 : 115; Median age = 58 (range: 19-89). Diseases included sarcomas (n = 88, 35%), NSCLC (n = 61, 24%), glioma (n = 42, 17%), melanoma (n = 7, 3%) and others (n = 55, 21%). Median turn-around time from consent to availability of report: 24 days (range: 3-112 days). 89% of samples passed quality control assessments. 8% (n = 21) of samples could not be processed due to insufficient material (n = 18), decalcified specimen (n = 2) and poor RNA quality (n = 1). 20 pts (9% of tested samples) had actionable genomic alterations identified that resulted in off-label use of directed anti-cancer therapies, referral to clinical trials or compassionate access programmes. These include EGFRvIII mutations (n = 7) and MET alterations (n = 2) in gliomas; ROS1 (n = 4), ALK (n = 2), MET exon 14-skipping (n = 1) and RET (n = 1) rearrangements in NSCLC; ALK rearranged sarcoma (n = 1). Across all diseases, 3 pts with NTRK fusions were identified.

Conclusions
We report the first institutional-based molecular profiling programme in Hong Kong. Such programmes are feasible in Asia. Pts can potentially benefit from identification of actionable alterations within a reasonable time frame and be channelled to appropriate therapies or clinical trials.
著者Loong H, Chow C, Ho K, Fung J, Koh J, Chan TC, Leung LK S, Yeo W, Ma B, Chan S L, Hui EP, Lee KWC, Wong ACY, Lam DCM, Wong KCW, Mok ST, To KF
會議名稱ESMO Asia 2019
會議開始日22.11.2019
會議完結日24.11.2019
會議地點Singapore
會議國家/地區新加坡
會議論文集題名Annals of Oncology
出版年份2019
月份11
卷號30
期次Suppl. 9
出版地Singapore
頁次ix124 - ix125
語言英式英語

上次更新時間 2021-21-02 於 23:39